Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Non-cash Items (2021 - 2025)

Historic Non-cash Items for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $398541.0.

  • Aligos Therapeutics' Non-cash Items rose 16576.49% to $398541.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $398541.0, marking a year-over-year increase of 16576.49%. This contributed to the annual value of $172072.0 for FY2024, which is 9715.57% down from last year.
  • As of Q3 2025, Aligos Therapeutics' Non-cash Items stood at $398541.0, which was up 16576.49% from $307792.0 recorded in Q2 2025.
  • In the past 5 years, Aligos Therapeutics' Non-cash Items ranged from a high of $24.5 million in Q3 2021 and a low of $149960.0 during Q3 2024
  • Its 5-year average for Non-cash Items is $4.3 million, with a median of $3.1 million in 2024.
  • Its Non-cash Items has fluctuated over the past 5 years, first surged by 233213.05% in 2023, then tumbled by 9725.93% in 2024.
  • Aligos Therapeutics' Non-cash Items (Quarter) stood at $16.8 million in 2021, then plummeted by 77.75% to $3.7 million in 2022, then skyrocketed by 62.19% to $6.0 million in 2023, then crashed by 97.16% to $172072.0 in 2024, then surged by 131.61% to $398541.0 in 2025.
  • Its Non-cash Items stands at $398541.0 for Q3 2025, versus $307792.0 for Q2 2025 and $251095.0 for Q1 2025.